NCT03936959: A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer

NCT03936959
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: MSI-H
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received at least 1 line of standard systemic therapy in the metastatic setting
Exclusions: Patients who have symptomatic central nervous system (CNS) malignancy or metastasis- see trial for details
https://ClinicalTrials.gov/show/NCT03936959

Comments are closed.

Up ↑